Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compound Zhebei granules plus venetoclax + azacitidine for relapsed/refractory AML
ChiCTR2400084082Phase 2Recruiting
- Sponsor
- Beijing University of Chinese Medicine
- Start
- May 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of compound zhebei granule, venetoclax and azacitidine in acute myeloid leukemia (AML) (2 arms), sponsored by Beijing University of Chinese Medicine. Primary endpoint: Objective response rate. Started May 2024; status: recruiting.
02
Drugs
compound zhebei granulevenetoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2400084082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084082.